201 related articles for article (PubMed ID: 37190811)
1. Insight into Tumor Hypoxia: Radionuclide-based Biomarker as Diagnostic Tools.
Saxena P; Gambhir S; Dixit M
Curr Top Med Chem; 2023; 23(12):1136-1154. PubMed ID: 37190811
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia imaging agents labeled with positron emitters.
Hoigebazar L; Jeong JM
Recent Results Cancer Res; 2013; 194():285-99. PubMed ID: 22918765
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia imaging using PET and SPECT: the effects of anesthetic and carrier gas on [Cu]-ATSM, [Tc]-HL91 and [F]-FMISO tumor hypoxia accumulation.
Kersemans V; Cornelissen B; Hueting R; Tredwell M; Hussien K; Allen PD; Falzone N; Hill SA; Dilworth JR; Gouverneur V; Muschel RJ; Smart SC
PLoS One; 2011; 6(11):e25911. PubMed ID: 22102855
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers.
Carlin S; Zhang H; Reese M; Ramos NN; Chen Q; Ricketts SA
J Nucl Med; 2014 Mar; 55(3):515-21. PubMed ID: 24491409
[TBL] [Abstract][Full Text] [Related]
5. β -[
Kumar P; Roselt P; Reischl G; Cullinane C; Beiki D; Ehrlichmann W; Binns D; Naimi E; Yang J; Hicks R; Machulla HJ; Wiebe LI
Curr Radiopharm; 2017; 10(2):93-101. PubMed ID: 28294075
[TBL] [Abstract][Full Text] [Related]
6.
Qian Y; Von Eyben R; Liu Y; Chin FT; Miao Z; Apte S; Carter JN; Binkley MS; Pollom EL; Harris JP; Prionas ND; Kissel M; Simmons A; Diehn M; Shultz DB; Brown JM; Maxim PG; Koong AC; Graves EE; Loo BW
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1183-1192. PubMed ID: 29859786
[TBL] [Abstract][Full Text] [Related]
7. Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia.
Bonnitcha PD; Bayly SR; Theobald MB; Betts HM; Lewis JS; Dilworth JR
J Inorg Biochem; 2010 Feb; 104(2):126-35. PubMed ID: 19932509
[TBL] [Abstract][Full Text] [Related]
8. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
9. Copper-64 based radiopharmaceuticals for brain tumors and hypoxia imaging.
Pasquali M; Martini P; Shahi A; Jalilian AR; Osso JA; Boschi A
Q J Nucl Med Mol Imaging; 2020 Dec; 64(4):371-381. PubMed ID: 33026209
[TBL] [Abstract][Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Ester Hydrolysis as a New Approach in Development of Positron Emission Tomography Tracers for Imaging Hypoxia.
Zhang L; Yao X; Cao J; Hong H; Zhang A; Zhao R; Zhang Y; Zha Z; Liu Y; Qiao J; Zhu L; Kung HF
Mol Pharm; 2019 Mar; 16(3):1156-1166. PubMed ID: 30676751
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
Kinoshita T; Fujii H; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H
Lung Cancer; 2016 Jan; 91():56-66. PubMed ID: 26711935
[TBL] [Abstract][Full Text] [Related]
13. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
Yuan H; Schroeder T; Bowsher JE; Hedlund LW; Wong T; Dewhirst MW
J Nucl Med; 2006 Jun; 47(6):989-98. PubMed ID: 16741309
[TBL] [Abstract][Full Text] [Related]
14. Imaging hypoxia in tumors.
Ballinger JR
Semin Nucl Med; 2001 Oct; 31(4):321-9. PubMed ID: 11710774
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia PET Tracers in EBRT Dose Planning in Head and Neck Cancer.
Hodolič M; Fettich J; Kairemo K
Curr Radiopharm; 2015; 8(1):32-7. PubMed ID: 25808959
[TBL] [Abstract][Full Text] [Related]
16. Recent advances on radionuclide labeled hypoxia-imaging agents.
Li Z; Chu T
Curr Pharm Des; 2012; 18(8):1084-97. PubMed ID: 22272826
[TBL] [Abstract][Full Text] [Related]
17. A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].
Furukawa T; Yuan Q; Jin ZH; Aung W; Yoshii Y; Hasegawa S; Endo H; Inoue M; Zhang MR; Fujibayashi Y; Saga T
Oncol Rep; 2015 Sep; 34(3):1379-87. PubMed ID: 26134305
[TBL] [Abstract][Full Text] [Related]
18. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of the hypoxia PET tracers [¹⁸F]HX4, [¹⁸F]FAZA, and [¹⁸F]FMISO in a preclinical tumor model.
Peeters SG; Zegers CM; Lieuwes NG; van Elmpt W; Eriksson J; van Dongen GA; Dubois L; Lambin P
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):351-9. PubMed ID: 25491505
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
